Randomized phase II Trials: A long-term investment with promising returns

Journal of the National Cancer Institute

Volumn 103, Issue 14, 2011, Pages 1093-1100

  Sharma, Manish R ^a   Stadler, Walter M ^a,b   Ratain, Mark J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; CRIZOTINIB; GEMCITABINE; IMATINIB; JANUS KINASE 3 INHIBITOR; PLACEBO; SORAFENIB; TUMOR MARKER; VEMURAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; BAYES THEOREM; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DRUG DEVELOPMENT; EPIDEMIOLOGY; ETHICS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NEUROLOGIC DISEASE; ONCOLOGY; OVERALL SURVIVAL; PANCREAS CANCER; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAMPLE SIZE; SIMULATION; STUDY DESIGN; TUMOR;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); ENDPOINT DETERMINATION; EVIDENCE-BASED MEDICINE; HEALTH RESOURCES; HUMANS; LIFE EXPECTANCY; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAMPLE SIZE; SELECTION BIAS; TIME FACTORS; TREATMENT FAILURE;

EID: 79960746726     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr218     Document Type: Review

References (61)

1. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood). 2006;25(2):420-428. (Pubitemid 43529550)
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-715. (Pubitemid 39173511)
3. Elias T, Gordian M, Singh N, et al. Why products fail in phase III. In Vivo. 2006;24:49-54.
4. Maitland ML, Hudoba C, Snider KL, Ratain MJ. Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res. 2010;16(21):5296-5302.
5. Michaelis LC, Ratain MJ. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res. 2007;13(8):2400-2405. (Pubitemid 46698590)
6. Sharma MR, Maitland ML, Ratain MJ. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. Cancer J. 2009;15(5):426-430.
7. Gan HK, Grothey A, Pond GR, et al. Randomized phase II trials: inevitable or inadvisable? J Clin Oncol. 2010;28(15):2641-2647.
8. Stewart DJ. Randomized phase II trials: misleading and unreliable. J Clin Oncol. 2010;28(31):649-650.
9. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol. 2008;26(8):1346-1354.
10. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527-534. (Pubitemid 351264344)
11. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742.
12. Vickers AJ, Ballen V, Scher HI. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing. Clin Cancer Res. 2007;13(3):972-976. (Pubitemid 46340375)
13. Rubinstein L, Crowley J, Ivy P, et al. Randomized phase II designs. Clin Cancer Res. 2009;15(6):1883-1890.
14. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23(31):8033-8040. (Pubitemid 46657405)
15. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2004;22(13):2610-2616. (Pubitemid 41103748)
16. Stathopoulos GP, Syrigos K, Polyzos A, et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Ann Oncol. 2004;15(2):224-229. (Pubitemid 38262619)
17. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001;92(3):569-577. (Pubitemid 32735192)
18. Kindler HL. The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer. 2002;95(4 suppl):928-932. (Pubitemid 34839688)
19. Louvet C, André T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol. 2002;20(6):1512-1518. (Pubitemid 34260530)
20. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002;20(5):1182-1191. (Pubitemid 34177423)
21. Berlin JD, Adak S, Vaughn DJ, et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology. 2000;58(3):215-218. (Pubitemid 30189904)
22. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28(22):3617-3622.
23. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28(22):3605-3610.
24. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25(16):2212-2217. (Pubitemid 46954645)
25. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24(24):3946-3952. (Pubitemid 46630743)
26. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16(10):1639-1645. (Pubitemid 41510138)
27. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23(15):3509-3516.
28. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22(18):3776-3783. (Pubitemid 41095218)
29. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20(15):3270-3275. (Pubitemid 34831525)
30. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966. (Pubitemid 46972777)
31. Walter RB, Appelbaum FR, Tallman MS, et al. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood. 2010;116(14):2420-2428.
32. Tang H, Foster NR, Grothey A, et al. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol. 2010;28(11):1936-1941.
33. Sharma M, Karrison T, Maitland ML, et al. VEGF pathway therapy: resampling positive phase III data to assess phase II trial designs and endpoints. J Clin Oncol. 2010;28(suppl):15s. Abstract 2520.
34. Stewart DJ, Whitney SN, Kurzrock R. Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol. 2010;28(17):2925-2935.
35. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
36. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
37. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645-652. (Pubitemid 34815868)
38. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472-480. (Pubitemid 34879334)
39. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116(24):5089-5102.
40. Ratain MJ, Karrison TG. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res. 2007;13(3):781-782. (Pubitemid 46340347)
41. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10. (Pubitemid 19099520)
42. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
43. Karrison TG, Maitland ML, Stadler WM, et al. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007;99(19):1455-1461.
44. Dancey JE, Dobbin KK, Groshen S, et al.; Biomarkers Task Force of the NCI Investigational Drug Steering Committee. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010;16(6):1745-1755.
45. Stadler W. Other paradigms: randomized discontinuation trial design. Cancer J. 2009;15(5):431-434.
46. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505-2512. (Pubitemid 46630627)
47. Escudier B, Eisen T, Stadler WM, et al.; Target Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134. (Pubitemid 46089673)
48. Olanow CW, Rascol O, Hauser R, et al.; Adagio Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-1278.
49. D'Agostino RB. The delayed-start study design. N Engl J Med. 2009;361(13):1304-1306.
50. Cheung YK, Inoue LY, Wathen JK, et al. Continuous Bayesian adaptive randomization based on event times with covariates. Stat Med. 2006;25(1):55-70. (Pubitemid 43136949)
51. Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials. 2009;6(3):205-216.
52. Lee JJ, Xuemin Gu, Suyu Liu. Bayesian adaptive randomization designs for targeted agent development. Clin Trials. 2010;7(5):584-596.
53. Thall PF, Simon R, Ellenberg SS. A two-stage design for choosing among several experimental treatments and a control in clinical trials. Biometrics. 1989;45(2):537-547. (Pubitemid 19165264)
54. Liu PY, Dahlberg S, Crowley J. Selection designs for pilot studies based on survival. Biometrics. 1993;49(2):391-398. (Pubitemid 23217975)
55. Liu PY, Dahlberg S. Design and analysis of multiarm clinical trials with survival endpoints. Control Clin Trials. 1995;16(2):119-130.
56. Storer BE. A sequential phase II/III trial for binary outcomes. Stat Med. 1990;9(3):229-235. (Pubitemid 20252731)
57. Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics. 2002;58(4):823-831. (Pubitemid 36133760)
58. Jenkins M, Stone A, Jennison C. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints [published online ahead of print]. Pharm Stat. 2010.
59. Harmon A. New drugs stir debate on rules of clinical trials. New York Times. September 19, 2010:A1.
60. Seymour L, Ivy SP, Sargent D, et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010;16(6):1764-1769.
61. Cannistra SA. Phase II trials in journal of clinical oncology. J Clin Oncol. 2009;27(19):3073-3076.